Comprehensive Analysis of JCHAIN as a Potential Prognostic Factor for Breast Cancer and an Indicator for Tumor Microenvironment.

Biomedicines · 2025 · PMC12561060 · PMID 41153653

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Since the PD-1 inhibitor (pembrolizumab) combined with chemotherapy has been approved as standard treatment for advanced triple-negative breast cancer with positive PD-L1 expression (CPS ≥ 10), there has been an increasing trend to target TME-interacting molecules, which could potentially moderate the cytotoxic effect of immune cells [ 7 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.